binds circulating fibrinogen (fib) or von Willebrand factor and cross-links platelets as the final common pathway to platelet aggregation. 5 Activated platelets express the integrin αIIbβ3 (also known as the activated platelet membrane GP IIb/IIIa receptor) on their surface, which binds fib. 6 Raised plasma fib concentrations increase the risk of vascular events. 7 Moreover, platelet hyperactivity has also been reported in several conditions where plasma fib concentrations are increased. [6] [7] [8] GP IIb/IIIa receptor antagonists are potent inhibitors because of the critical role that fib binding plays in platelet aggregation. 5 To date, the US Food and Drug Administration has approved 3 GP IIb/IIIa antagonists: abciximab (a chimeric monoclonal antibody 7E3 Fab fragment), eptifibatide (a cyclic heptapeptide based on the KGD amino acid sequence), and tirofiban (a nonpeptide tyrosine derivative). 5, 9 Tirofiban hydrochloride, L-tyrosine-N-(butylsulfonyl)-O-[-4-(4-piperidinylbutyl)] monohydrochloride,
Introduction
There is evidence linking platelet hyperactivity with vascular events. 1 For example, patients with more activated platelets had a higher incidence of myocardial infarction (MI) and early restenosis. 2 Platelet activation may also play a role in the pathogenesis of complications after percutaneous coronary intervention (PCI) and stent implantation. 3 Patients with hyperactive platelets may benefit more from intensive antiplatelet therapy as platelet inhibitors significantly reduce the risk of vascular events. 1, 4 One way to inhibit platelets is to block the platelet membrane glycoprotein (GP) IIb/IIIa receptor, which There is evidence linking raised plasma fibrinogen (fib) and platelet hyperactivity with vascular events. One way to inhibit platelets is to block the platelet membrane glycoprotein (GP) IIb/IIIa receptor, which binds circulating fib or von Willebrand factor and cross-links platelets at the final common pathway to platelet aggregation. Tirofiban is a potent and specific fib receptor antagonist, used in the treatment of unstable angina. The authors assessed the effect of tirofiban on spontaneous platelet aggregation (SPA), fib-induced, serotonin (5HT)-induced, and adenosine diphosphate (ADP)induced aggregation in whole blood by calculating the percentage free platelet count. These various agonists were used alone and in combination. The authors also measured the effect of tirofiban on agonists-induced (ADP, 5HT) platelet shape change (PSC). The effect of fib on PSC was also evaluated in platelet-rich plasma using a high-resolution (0.07 fL) channelyzer. Tirofiban significantly inhibited SPA, fib (2, 4, 8 g/L), ADP, ADP + fib combination, and 5HT-induced aggregation. Tirofiban had no effect on agonist-induced PSC. There was no apparent change in platelet volume with fib. In conclusion, tirofiban does not appear to have an effect on PSC, an early phase of platelet activation. Tirofiban seems to be a nonspecific and an effective inhibitor of platelet aggregation (a later phase of platelet activation) in whole blood. The clinical significance of these findings remains to be established. Keywords: fibrinogen; platelet aggregation; platelet shape change; platelet volume; tirofiban; glycoprotein IIb/IIIa is a potent and specific fib receptor antagonist and is approved (under the name Aggrastat) for use in the prevention of the progression of unstable angina to MI. 5, 9, 10 Other intravenous agents directed against the GP IIb/IIIa receptors include abciximab, eptifibatide, and a nonpeptide mimetic, lamifiban. 11 Clinical trials including more than 18 000 patients have shown the benefits of intravenous GP IIb/IIIa blockade. 12 The safety and efficacy of these GP IIb/IIIa antagonists have also been evaluated initially in patients undergoing PCI. More than 20 000 patients were enrolled in 9 major studies of abciximab, eptifibatide, and tirofiban. 2, 13, 14 The result of all these trials was the widespread use of GP IIb/IIIa antagonists. 2, 13, 14 In the present study, we assessed the effect of tirofiban on spontaneous platelet aggregation (SPA), as well as fib-induced, serotonin-induced (5-hydroxytryptamine, 5HT), and adenosine diphosphate (ADP)-induced aggregation. We used these various agonists alone and in combination. The rationale was that because ADP is an important aggregating agent, and raised plasma fib concentrations increase the risk of vascular disease, it would be useful to evaluate the inhibitory effect of tirofiban in this model. Also, circulating levels of agonists (eg, 5HT or ADP) on their own may not have any effect on platelets but in combination may produce a synergistic effect (eg, aggregation, stimulating vascular smooth muscle proliferation, and inducing vasoconstriction in atheromatous coronary vessels). 15 We also investigated the effect of tirofiban on a combination of fib and ADP at subthreshold concentrations. Others have shown that optimal platelet aggregation occurs when using pairs of agonists (eg, ADP + epinephrine and epinephrine + collagen) even when each of the agonists is added to the other at subthreshold doses. 16 Another study demonstrated that the platelet surface expression of the functional GP IIb/IIIa is required for 5HT release from δ-granules. 17 Therefore, we investigated the effect of tirofiban on 5HT-induced platelet aggregation.
We also assessed the effect tirofiban on 5HTinduced and ADP-induced platelet shape change (PSC), an early phase of platelet activation that precedes aggregation. [18] [19] [20] In this study, we determined whether fib alone or in combination with another agonist affects PSC, because to our knowledge this has not been investigated using a high-resolution channelyzer.
Materials and Methods
Fib type I from human plasma, approximately 60% protein (more than 90% of protein clottable) containing approximately 15% sodium citrate and approximately 25% sodium chloride; adenosine diphosphate (ADP); serotonin creatinine sulfate (5HT); and glutaraldehyde grade II (25% aqueous solution) were obtained from Sigma Chemicals (Poole, UK). Isoton II was from Beckman Coulter (Luton, UK). Tirofiban was kindly donated by Merck Sharp and Dohme Ltd (Hertfordshire, UK).
Whole Blood (WB) Aggregation
Venous blood was collected in 3.8% citrate (1 part citrate to 9 parts blood) from healthy volunteers. Details of the number of volunteers used in each experiment are given in the relevant results sections below. All the volunteers denied taking any drugs for at least 2 weeks prior to sampling. Aliquots of 1 ml WB were incubated at 37°C for 15 minutes prior to the start of the experiments. SPA was assessed at specific time points (0, 5, 10, 15, and 20 minutes) as previously described. 1, 7, 8, 19 Briefly, the blood samples were placed in siliconized aggregometer cuvettes and stirred using a Teflon-coated magnetic stirrer during the experiments. The samples were maintained at 37°C in a Chronolog whole blood aggregometer 540 (Coulter Electronics; Luton, Beds, UK) throughout the experiments. Blood samples were then withdrawn from the aggregometer cuvettes and the platelet count determined using a Coulter ACT Diff Analyzer (Coulter Electronics). The results are expressed as percentage free platelet count. For example, if the baseline count was 300 × 10 9 /L and this fell to 200 × 10 9 /L at a later time, then the percentage free count is 200/300 × 100 = 67%.
The effect of tirofiban on SPA was assessed after WB was stirred with the following combinations: saline control/SPA and tirofiban only (50 ng/mL). The effect of tirofiban on fib only was also assessed when WB was stirred with fib only (2, 4, 8 g/L), and then tirofiban (500 ng/mL) + fib (2, 4, and 8 g/L) and aggregation measured at the same time points (0, 5, 10, 15, and 20 minutes) as above.
We also evaluated ADP (5 μM)-induced aggregation. WB was then incubated with tirofiban (500 ng/mL) for 5 minutes after which ADP (5 μM) was added and aggregation determined at 0, 5, 10, 15, and 20 minutes.
The effect of tirofiban on WB aggregation induced by a combination of agonists at subthreshold concentrations was measured over a specified time period (1, 3, 5, 10, 15, and 20 minutes). Thus, we assessed saline (control), ADP (1 μM), fib (0.5 g/L), and a combination of ADP (1 μM) plus fib (0.5 g/L). Because we were using lower doses of agonists, we looked at the effect of the lower dose of tirofiban (250 ng/mL) on this combination by first incubating WB with tirofiban (250 ng/mL) for 5 minutes before adding the combination of ADP (1 μM) plus fib (0.5 g/L).
To assess the effect of tirofiban on 5HT-induced aggregation, 5HT (5 μM) was added and aggregation assessed at several time points (1, 3, 5, 10, 15, and 20 minutes) as previously described. 21 Then WB was incubated with tirofiban (500 ng/mL) for 5 minutes and 5HT (5 μM) was added before measuring aggregation again.
Median Platelet Volume (MPV) Measurement
Venous blood was collected in 3.8% citrate (1 part citrate to 9 parts blood) from healthy volunteers. All the volunteers denied taking any drugs for at least 2 weeks prior to sampling. Details of the number of volunteers used in each experiment are given in the relevant sections below. Citrated blood was centrifuged at 160g for 15 minutes at room temperature. Platelet-rich plasma (PRP) was then carefully collected with a Pasteur pipette. Aliquots of PRP (450 μL), in siliconized glass cuvettes, were placed in a Chronolog dual-channel optical aggregometer (Coulter Electronics) and kept at 37°C for 15 minutes prior to the start of the experiments detailed below. The specific times for adding agonists and antagonists were based on preliminary experiments and our previous publications. [18] [19] [20] 22 PRP was stirred using a Teflon-coated metal stir bar at 1000 rpm. We adjusted the concentration of agonists and sampling times to obtain a middle range response that could be either inhibited or enhanced as determined in previous studies. [18] [19] [20] 22 PRP collected from 7 healthy volunteers was incubated with tirofiban (50-500 ng/mL) for 3 to 5 minutes without stirring and then either ADPinduced (0.2-0.4 μM) or 5HT-induced (0.25-0.5 μM) PSC was measured after 30 seconds and 1 minute as outlined below. ADP-induced or 5HTinduced PSC was again assessed at the same concentrations but without tirofiban.
We also assessed the effect of fib-induced (1-8 g/L) PSC with and without tirofiban (125-500 ng/mL) at various time points (between 30 seconds and 20 minutes). In addition, lower concentrations of fib (0.5-1.5 g/L) was used in combination with 5HT (0.25 μM) or ADP (0.2 μM) and MPV was assessed (after 30 seconds and 1 minute) as described below.
At relevant time points, 100-μL aliquots of PRP were removed and mixed with 400 μL of fixative (4% aqueous glutaraldehyde). This sample was further diluted 400-fold in Isoton II. The MPV of these samples was then assessed using a Coulter ZM counter (electrical impedance method with a 70-μm diameter sampling tube orifice) coupled to a C-256 channelyzer (Coulter Electronics). The resolution of the channelyzer is 0.07 fL. The analyzer sample "window" was set between 2.67 and 19.12 fL. [18] [19] [20] 22 The counter was calibrated using 9-fL latex particles (Coulter Electronics). For particle analysis, data were accumulated to a maximum of 500 platelets in each of the 256 channels. The MPV is the volume of the channel on each side of which 50% of the platelet population is distributed. [18] [19] [20] 22 The increase in MPV was taken as representing the PSC. Saline (control) was added to samples to match those of the agonist (as 10-50-μL volumes) at the same time points. The platelet count was monitored throughout the experiment to exclude PRP samples where significant (>5%) aggregation occurred. [18] [19] [20] 22 
Statistical Analysis and Presentation of Results
Statistical analysis was performed using GraphPad Prism Version 4 (Graph Pad Software, Inc; San Diego, CA). Comparisons were carried out using paired t tests (or nonparametric tests) Results are expressed as mean ± standard deviation and a P < .05 was considered significant.
Results

WB Aggregation
Tirofiban (50 ng/mL) significantly inhibited SPA at all time points (5-20 minutes). Table 1 shows statistical comparisons.
The 2-g/L concentration of fib demonstrated a similar trend of platelet aggregation over time as the saline control. In contrast, the 4-g/L concentration of fib significantly increased platelet aggregation after 5 minutes (P = .002), 10 minutes (P = .033), and 15 minutes (P = .05, n = 8; see Table 2 ). Tirofiban (500 ng/mL) significantly inhibited the fib (4 g/L)-enhanced platelet aggregation. A similar pattern of aggregation and inhibition of aggregation was observed with 8-g/L concentration of fib and tirofiban (500 ng/mL), respectively. The addition of tirofiban to WB produced aggregation that was even less than that observed with the saline control (Table 2 shows statistical comparisons, and Figure 1 is a representative curve of this effect).
There was significant inhibition of ADP (5 μM)induced platelet aggregation by tirofiban (500 ng/mL) at all time points (Table 3) .
A lower concentration of fib (0.5 g/L) demonstrated a similar platelet aggregation pattern as the saline control. ADP (1 μM)-induced platelet aggregation showed an expected transient significant increase in aggregation as compared with the saline control at 1 minute and 3 minutes (96 ± 5 vs 39 ± 21, P = .001, and 92 ± 4 vs 71 ± 17, P = .035, respectively). Beyond these sampling times, there was aggregation but it was not significant in comparison with saline (see Figure 2 ). The effect of a very low dose of ADP (1 μM) in combination with a very low dose of fib (0.5 g/L) on platelet aggregation followed a similar pattern as ADP over time, with no significant additive aggregating effect ( Figure 2 ). Tirofiban (250 ng/mL) significantly inhibited platelet aggregation induced by this ADP + fib combination at all time points to a level that was even better than saline on its own (Table 4 shows statistical analysis, and Figure 2 shows a representative curve).
There was an expected increase in 5HT (5 μM)induced aggregation over time in comparison with the saline control. This aggregation was significantly inhibited by tirofiban (500 ng/mL; Table 5 shows comparisons).
MPV Measurement
There was the expected significant increase in MPV (fL) when ADP-induced PSC was compared with saline control (mean ± standard deviation: 5.79 ± 0.55 vs 6.09 ± 0.55, P = .0001; n=7). Tirofiban (50-500 ng/mL) had no significant inhibitory effect on this increase in PSC (6.09 ± 0.55 vs 6.12 ± 0.55, NS; n = 7).
The effect of tirofiban on 5HT-induced PSC followed the same trend as above. Thus, 5HT (6.12 ± 0.49 fL) versus saline control (5.79 ± 0.57 fL) demonstrated a significant increase in MPV (P = .0004; n = 7). However, tirofiban (50-500 ng/mL) did not show any inhibitory effect on this response (6.12 ± 0.49 vs 6.14 ± 0.50, NS; n = 7). Effect of Tirofiban on Fibrinogen/Agonist-Induced PSC / Jagroop, Mikhailidis 299 Results are expressed as mean ± standard deviation and compare the percentage free platelet count. Seven healthy volunteers were evaluated. We also evaluated the effect of fib (0.5-2 g/L) on MPV at various time points (between 1 and 20 minutes). There was no apparent change in MPV (n = 7) when compared with saline controls (a representative result from 1 subject is demonstrated below). Thus, MPV at the given time points are illustrated for saline control, for example, 1 minute, 6.18 fL; 3 minutes, 6.12 fL; 5 minutes, 6.18 fL; 10 minutes, 6.06 fL; 15 minutes, 6.06 fL, and 20 minutes, 6.06 fL. For fib (2 g/L) at the same time points the following results were obtained: 1 minute, 6.12 fL; 3 minutes, 6.12 fL; 5 minutes, 5.99 fL; 10 minutes, 5.93 fL; 15 minutes, 6.12 fL, and 20 minutes, 6.12 fL. Also, there was no additive MPV effect when fib (0.5-1.5 g/L) was used in combination with 5HT (0.25 μM) or ADP (0.2 μM; results not shown).
Discussion
PSC is an early phase of platelet activation that precedes platelet aggregation. Our technique of assessing PSC is highly sensitive (resolution 0.07 fL) 18, 20, 22 when compared with others who used less sensitive methods. 23, 24 We found that fib (0.5-2 g/L) had no effect on PSC at various time points (between 1 and 20 minutes), which was in agreement with the findings of others. 25 Also, ADP-induced and 5HT-induced PSC was not inhibited by tirofiban (50-250 ng/mL), a potent and specific GP IIb/IIIa receptor antagonist. We therefore suggest that PSC can occur independently of fib. In support of our findings, others demonstrated that when platelets were pretreated with ethylene glycol tetraacetic acid (which dissociates the integrin αIIbβ3) or preincubated with RGDS (a fib receptor antagonist), PSC induced by YFLLRNP (a cloned thrombin receptor ligand) still occurred. 25 Furthermore, PSC was measured in washed platelets (no fib added) by recording light transmission. 25 Our technique of measuring PSC uses PRP, and its preparation may influence various aspects of platelet function. 26 We used WB platelet aggregation, which offers rapid results without imposing too many changes on the platelet population. The choice of anticoagulant is also important. Citrate anticoagulation can demonstrate falsely high estimates of efficacy of eptifibatide because of the lowering of ionized calcium levels. 27 Storey et al 26 also showed that eptifibatide was markedly more effective both in WB and in PRP (P < .0005) when citrate was used as an anticoagulant rather than hirudin (a direct thrombin inhibitor that maintains physiological calcium ion levels). We have also shown that a low-molecular-weight heparin activates platelets less than unfractionated heparins. 19 In this study, fib on its own showed significantly increased WB platelet aggregation compared with the saline control. Increased circulating levels of fib is an emerging predictor of vascular events. 6, 7 Fib levels are raised in patients with vascular disease. 6 Fib also plays an important role in platelet aggregation by linking activated platelets. 6, 7 It is therefore advantageous to inhibit fib-induced platelet aggregation.
GP IIb/IIIa receptor antagonists are very potent inhibitors because of the critical role fib binding plays in platelet aggregation. 5, 28 When administered intravenously, these drugs are effective as adjuvant therapy in PCI and in acute coronary syndromes. 2, 13, 14 The approval of tirofiban covers conservative treatment of MI and unstable angina, as well as PCI intervention. 10 The in vitro concentration of tirofiban we used to achieve complete inhibition of fib was 500 ng/mL. Mukherjee and Roffi 29 stated that a lower dose of tirofiban (10 μg/kg bolus) followed by 0.15 μg/kg/min infusion was inferior to the standard dose of abciximab in patients with PCI. 29 This was possibly because of insufficient platelet inhibition at this low dose. Thus, when a high-bolus dose of tirofiban (25 μg/kg) was administered followed by the standard infusion, tirofiban was as effective as abciximab with comparable safety. 29 Storey et al 26 also showed that higher concentrations (100-1500 nmol/L) of GP IIb/IIa antagonists (eptifibatide, M0852, and GR144053) were required to inhibit platelet aggregation in WB compared with PRP turbidimetry. That is to say that a 3-fold higher concentration of eptifibatide was required to inhibit ADP-induced microaggregate formation (aggregation in WB or PRP) than was required to inhibit macroaggregate formation (PRP turbidimetry). 26 This may explain why in our preliminary experiments with agonists-induced aggregation lower doses (50 ng/mL) of tirofiban only partially inhibited agonistinduced platelet aggregation. Thus, we decided to use higher concentrations (250-500 ng/mL). However, tirofiban at the lower concentration (50 ng/mL) did significantly inhibit SPA (Table 1) . At the higher concentrations of tirofiban (250-500 ng/mL) we observed complete inhibition of ADP-induced as well as 5HTinduced platelet aggregation, to a level even better than the saline baseline value (Tables 3 and 5 ). Also, tirofiban inhibited platelet aggregation induced by a combination of agonists (ADP + fib, Table 4 ).
The oral GP IIb/IIIa inhibitors showed no benefit or even increased mortality in clinical trials. 30 There are a number of possible reasons for their failure, including low bioavailability that led to a large peaktrough difference. 30 Furthermore, most GP IIb/IIIa antagonists can exert partial agonism. 30 In the presence of high drug levels, this is not a problem; however, the low trough levels with oral inhibitors can lead to increased platelet aggregation. 30 This rationale supports the need to achieve higher circulating levels of GP IIb/IIIa. Furthermore, in a clinical setting, despite the administration of a GP IIb/IIa inhibitor the platelets may be "primed" (because PSC can occur). Therefore, inhibiting PSC (eg, by administering aspirin, clopidogrel, or both drugs together with a GP IIb/IIa inhibitor) may be very relevant. In this context, we previously evaluated the effect of aspirin (75 mg/day) and clopidogrel (75 mg/day) on platelet function in patients with peripheral arterial disease. 31 These antiplatelet agents inhibited both PSC and aggregation after oral administration to these patients.
The risk-benefit ratio of GP IIb/IIIa antagonists may be because of differential effects on microaggregation and macroaggregation. 26 It appears that it may be easier to inhibit the formation of larger aggregates of platelets (macroaggregates) than to prevent pairing of platelets and formation of smaller aggregates (microaggregates). 26 The hypothesis is that different GP IIb/IIIa antagonists will have different ratios of affinities for the resting receptor and the activated receptor. Moreover, the differences in the outcome of studies evaluating the effect of GP IIb/IIIa antagonists on death and MI 32 may relate to the levels of these drugs and their effects on inhibition of microaggregation. 26 We conclude that tirofiban significantly inhibited agonist (ADP, 5HT)-induced platelet aggregation. Also, this GP IIb/IIIa receptor antagonist inhibited SPA in vitro. Tirofiban appears to be nonspecific because it inhibited aggregation induced not only by fib (even at a very high concentration of 8 g/L; results not shown) but also by other agonists used alone or in combination. However, tirofiban did not have an effect on PSC. Further studies are needed to confirm our findings and define their clinical significance.
